Development of Coagulation Factor XII Antibodies for Inhibiting Vascular Device-Related Thrombosis.

ABSTRACT:

Introduction

Vascular devices such as stents, hemodialyzers, and membrane oxygenators can activate blood coagulation and often require the use of systemic anticoagulants to selectively prevent intravascular thrombotic/embolic events or extracorporeal device failure. Coagulation factor (F)XII of the contact activation system has been shown to play an important role in initiating vascular device surface-initiated thrombus formation. As FXII is dispensable for hemostasis, targeting the contact activation system holds promise as a significantly safer strategy than traditional antithrombotics for preventing vascular device-associated thrombosis.

Objective

Generate and characterize anti-FXII monoclonal antibodies that inhibit FXII activation or activity.

Methods

Monoclonal

SUBMITTER: Kohs TCL 

PROVIDER: S-EPMC8010086 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature